These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach. Xu MM; Zhou MT; Li SW; Zhen XC; Yang S J Neurosci Res; 2021 May; 99(5):1308-1324. PubMed ID: 33634546 [TBL] [Abstract][Full Text] [Related]
23. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Sheinerman KS; Toledo JB; Tsivinsky VG; Irwin D; Grossman M; Weintraub D; Hurtig HI; Chen-Plotkin A; Wolk DA; McCluskey LF; Elman LB; Trojanowski JQ; Umansky SR Alzheimers Res Ther; 2017 Nov; 9(1):89. PubMed ID: 29121998 [TBL] [Abstract][Full Text] [Related]
24. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease. Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266 [TBL] [Abstract][Full Text] [Related]
25. Extracellular miRNA biomarkers in neurologic disease: is cerebrospinal fluid helpful? Dhawan A Biomark Med; 2021 Oct; 15(15):1377-1388. PubMed ID: 34514843 [No Abstract] [Full Text] [Related]
26. Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study. Kaipainen A; Jääskeläinen O; Liu Y; Haapalinna F; Nykänen N; Vanninen R; Koivisto AM; Julkunen V; Remes AM; Herukka SK J Alzheimers Dis; 2020; 75(3):751-765. PubMed ID: 32310181 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Baldacci F; Lista S; Cavedo E; Bonuccelli U; Hampel H Expert Rev Proteomics; 2017 Apr; 14(4):285-299. PubMed ID: 28281838 [TBL] [Abstract][Full Text] [Related]
28. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. Szalárdy L; Zádori D; Klivényi P; Vécsei L J Alzheimers Dis; 2016 May; 53(2):373-92. PubMed ID: 27163812 [TBL] [Abstract][Full Text] [Related]
29. Life sciences: Biomarkers on the brain. Katsnelson A Nature; 2011 Nov; 479(7371):139-40. PubMed ID: 22103003 [No Abstract] [Full Text] [Related]
30. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. Paterson RW; Heywood WE; Heslegrave AJ; Magdalinou NK; Andreasson U; Sirka E; Bliss E; Slattery CF; Toombs J; Svensson J; Johansson P; Fox NC; Zetterberg H; Mills K; Schott JM Transl Psychiatry; 2016 Nov; 6(11):e952. PubMed ID: 27845782 [TBL] [Abstract][Full Text] [Related]
31. Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. van Waalwijk van Doorn LJ; Koel-Simmelink MJ; Haußmann U; Klafki H; Struyfs H; Linning P; Knölker HJ; Twaalfhoven H; Kuiperij HB; Engelborghs S; Scheltens P; Verbeek MM; Vanmechelen E; Wiltfang J; Teunissen CE J Neurochem; 2016 Apr; 137(1):112-21. PubMed ID: 26748905 [TBL] [Abstract][Full Text] [Related]
32. The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. Mazzucchi S; Palermo G; Campese N; Galgani A; Della Vecchia A; Vergallo A; Siciliano G; Ceravolo R; Hampel H; Baldacci F Expert Rev Proteomics; 2020; 17(7-8):543-559. PubMed ID: 33028119 [TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor-β1 in the cerebrospinal fluid of patients with distinct neurodegenerative diseases. Masuda T; Itoh J; Koide T; Tomidokoro Y; Takei Y; Ishii K; Tamaoka A J Clin Neurosci; 2017 Jan; 35():47-49. PubMed ID: 27756506 [TBL] [Abstract][Full Text] [Related]
34. Biomarkers for neurodegenerative diseases. Hansson O Nat Med; 2021 Jun; 27(6):954-963. PubMed ID: 34083813 [TBL] [Abstract][Full Text] [Related]
35. Applying fluid biomarkers to Alzheimer's disease. Zetterberg H Am J Physiol Cell Physiol; 2017 Jul; 313(1):C3-C10. PubMed ID: 28424166 [TBL] [Abstract][Full Text] [Related]
36. Diagnostic and Therapeutic Potential of Exosomal MicroRNAs for Neurodegenerative Diseases. He M; Zhang HN; Tang ZC; Gao SG Neural Plast; 2021; 2021():8884642. PubMed ID: 34054944 [TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. Parnetti L; Eusebi P; Lleó A Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974 [TBL] [Abstract][Full Text] [Related]
39. Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy. Coppi E; Ferrari L; Santangelo R; Caso F; Pinto P; Passerini G; Comi G; Magnani G Neurol Sci; 2014 May; 35(5):785-7. PubMed ID: 24487699 [TBL] [Abstract][Full Text] [Related]
40. Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases. Xia X; Wang Y; Zheng JC Transl Neurodegener; 2022 Dec; 11(1):53. PubMed ID: 36510311 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]